Transactions & Strategy

Once a strategic alternatives process begins, optionality narrows quickly. What starts as an open exploration of paths forward — partnerships, capital raises, divestitures, mergers — rapidly becomes a constrained decision environment where governance discipline matters more than at any other time. The Paradox of Strategic Alternatives The term strategic alternatives implies breadth — a deliberate assessment of all available options. In practice, the process creates its own mo

Transaction diligence in regulated medical technology environments is less about financial modeling and more about identifying where risk resides — technically, operationally, and organizationally. Yet many diligence processes remain disproportionately focused on valuation mechanics while underweighting the product, regulatory, and quality-system factors that ultimately determine whether a deal creates or destroys value. Where the Real Risk Lives In medtech transactions, the